$7.620
+0.226 (+2.97%)收盤時
NLSP 資訊
NLSP 事件
NLS Pharmaceutics Declares 1-for-10 Reverse Stock Split
NLS Pharmaceutics announced that it intends to effect a reverse share split of the company's issued and outstanding common shares, par value CHF 0.03 per share, at a ratio of 1-for-10. The company's common shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on October 31, under the new trading symbol (NCEL), and new name, NewcelX, following the anticipated closing of the merger with Kadimastem.
NLS Pharmaceutics Teams Up with Kadimastem and TargetGene for Collaboration
NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage biotechnology company developing breakthrough cell therapy solutions for severe diseases such as ALS and diabetes, announced the signing of a Memorandum of Understanding between Kadimastem and TargetGene Biotechnologies, which deals in precision gene-editing technologies. This collaboration brings together Kadimastem's proprietary cell therapy platforms with TargetGene's DNA-guided gene-editing platform, enabling highly specific, multiplexed genome modifications with minimal off-target activity. The collaboration is expected to continue under the combined company, NewCelX, upon completion of the anticipated merger between NLS and Kadimastem. Pursuant to the MOU, the companies will jointly develop and optimize gene-edited cell therapy products. The MOU establishes a framework for joint R&D activities, technology exchange, and future licensing opportunities.
NLS Pharmaceutics Secures Nasdaq Listing Approval
NLS Pharmaceutics and Kadimastem announced an update regarding the proposed merger. On October 21, NLS received an approval letter from the Nasdaq Listing Center for the listing of its common shares and the trading of the company on the Nasdaq Capital Market after completion of the Merger, under NLS's new name, NewcelX Ltd., with its new trading symbol for its common shares, (NCEL). Accordingly, the closing of the merger is expected to close on October 30 with the transition to trading under the combined company's new name beginning October 31, subject to fulfillment of the remaining customary closing conditions.
NLS Pharmaceutics and Kadimastem Receive Hong Kong Patent for Diabetes Treatment
NLS Pharmaceutics' merger partner Kadimastem has been granted a patent by the Hong Kong Intellectual Property Department covering Kadimastem's proprietary cell selection and enrichment technology used in the development of IsletRx, a stem cell-derived therapy candidate intended to treat-and potentially cure-insulin-dependent diabetes. According to Kadimastem, the Hong Kong patent adds to previously granted patents in Europe, the United States and India, further strengthening the global protection around IsletRx. The patented process enables the selection and enrichment of highly functional islet cells from differentiated cell populations to help maximize therapeutic effect.
NLS Pharmaceutics merger partner Kadimastem wins milestone payment
NLS Pharmaceutics announced that the Israel-U.S. Binational Industrial Research and Development Foundation, or Bird Foundation, has approved another milestone-based funding payment to Kadimastem, a clinical-stage cell therapy company developing "off-the-shelf," allogeneic regenerative treatments for neurodegenerative diseases and diabetes, with a U.S.-based company, iTolerance. The milestone payment is based on the progress demonstrated by the companies in the co-development of iTOL-102, a novel cell therapy targeting a potential cure for Type 1 diabetes without the need for life-long immunosuppression. Kadimastem's IsletRx technology is combined with iTolerance's proprietary iTOL-100 immunomodulatory platform in iTOL-102. The milestone payment approved by the BIRD Foundation amounts to approximately $166K, bringing the total support from the BIRD Foundation to $882,352 to date. The companies are currently preparing for safety toxicology studies and the initiation of clinical trial submissions based on FDA guidance. NLS CEO Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics, stated: "We are encouraged by the continued external validation and momentum in the iTOL-102 program, particularly as the merged company prepares to initiate key clinical studies in diabetes. This milestone further reinforces the strong scientific and strategic rationale behind our proposed merger with Kadimastem."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。